Quarterly report pursuant to Section 13 or 15(d)

Shareholders Equity and Capital Stock

v3.24.1.u1
Shareholders Equity and Capital Stock
3 Months Ended
Mar. 31, 2024
Shareholders Equity and Capital Stock  
Shareholders' Equity And Capital Stock

12.  Shareholders’ Equity and Capital Stock

 

Common shares

 

The Company’s share capital consists of an unlimited amount of Class A preferred shares authorized, without par value, of which no shares are issued and outstanding; and an unlimited amount of common shares authorized, without par value, of which 281,626,324 shares and 270,898,900 shares were issued and outstanding as of March 31, 2024, and December 31, 2023, respectively.

 

On February 21, 2023, the Company closed an underwritten public offering of 34,000,000 common shares and accompanying warrants to purchase up to 17,000,000 common shares, at a combined public offering price of $1.18 per common share and accompanying warrant. The warrants have an exercise price of $1.50 per whole common share and will expire three years from the date of issuance. Ur-Energy also granted the underwriters a 30-day option to purchase up to an additional 5,100,000 common shares and warrants to purchase up to 2,550,000 common shares on the same terms. The option was exercised in full. Including the exercised option, Ur-Energy issued a total of 39,100,000 common shares and accompanying warrants to purchase up to 19,550,000 common shares. The gross proceeds to Ur-Energy from this offering were approximately $46.1 million. After fees and expenses of $3.0 million, net proceeds to the Company were approximately $43.1 million.

 

During the three months ended March 31, 2024, the Company sold 2,464,500 common shares through its At Market facility for $4.2 million. After issue costs of $0.1 million, net proceeds to the Company were $4.1 million. The Company also received $11.1 million from the exercise of 16,376,500 warrants for 8,188,250 underlying common shares, and less than $0.1 million from the exercise of 74,674 stock options.

 

Stock options

 

In 2005, the Company’s Board of Directors approved the adoption of the Company's stock option plan (the “Option Plan”). The Option Plan was most recently approved by the shareholders on June 2, 2023. Eligible participants under the Option Plan include directors, officers, employees, and consultants of the Company. Under the terms of the Option Plan, grants of options will vest over a three-year period: one-third on the first anniversary, one-third on the second anniversary, and one-third on the third anniversary of the grant. The term of the options is five years.

 

Activity with respect to stock options is summarized as follows:

 

Stock Option Activity

 

Outstanding

Options

 

 

Weighted-average

Exercise Price

 

December 31, 2023

 

 

8,900,335

 

 

 

0.87

 

 

 

 

 

 

 

 

 

 

Exercised

 

 

(74,674 )

 

 

0.55

 

 

 

 

 

 

 

 

 

 

March 31, 2024

 

 

8,825,661

 

 

 

0.86

 

The exercise price of a new grant is set at the closing price for the shares on the Toronto Stock Exchange (TSX) on the trading day immediately preceding the grant date and there is no intrinsic value as of the date of grant.

 

We received less than $0.1 million from options exercised in the three months ended March 31, 2024.

 

Stock-based compensation expense from stock options was $0.2 million for the three months ended March 31, 2024, and $0.2 million for the three months ended March 31, 2023.

 

As of March 31, 2024, there was approximately $1.5 million of unamortized stock-based compensation expense related to the Option Plan. The expenses are expected to be recognized over the remaining weighted-average vesting period of 2.2 years under the Option Plan.

 

As of March 31, 2024, outstanding stock options are as follows:

  

 

 

 

 Options Outstanding

 

 

 Options Exercisable

 

 

Exercise

Price

 

 

Number

of Options

 

 

Weighted-average

Remaining Contractual

Life

 

 

 Aggregate

Intrinsic

Value

 

 

Number

of

 Options

 

 

 Weighted-average

Remaining Contractual

Life

 

 

 Aggregate

Intrinsic

Value

 

 

 Expiry

$

 

 

#

 

 

years

 

 

$

 

 

#

 

 

years

 

 

$

 

 

 

 

0.58

 

 

 

2,220,584

 

 

 

0.6

 

 

 

2,257,237

 

 

 

2,220,584

 

 

 

0.6

 

 

 

2,257,237

 

 

2024-11-05

 

0.47

 

 

 

2,568,652

 

 

 

1.6

 

 

 

2,914,603

 

 

 

2,568,652

 

 

 

1.6

 

 

 

2,914,603

 

 

2025-11-13

 

1.06

 

 

 

1,302,672

 

 

 

2.4

 

 

 

698,774

 

 

 

925,045

 

 

 

2.4

 

 

 

496,209

 

 

2026-08-27

 

1.65

 

 

 

175,000

 

 

 

3.0

 

 

 

-

 

 

 

116,666

 

 

 

3.0

 

 

 

-

 

 

2027-03-14

 

1.14

 

 

 

1,322,528

 

 

 

3.8

 

 

 

601,975

 

 

 

434,906

 

 

 

3.8

 

 

 

197,956

 

 

2028-01-04

 

1.52

 

 

 

1,236,225

 

 

 

4.7

 

 

 

97,024

 

 

 

-

 

 

 

-

 

 

 

-

 

 

2028-12-07

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

0.86

 

 

 

8,825,661

 

 

 

2.3

 

 

 

6,569,613

 

 

 

6,265,853

 

 

 

1.5

 

 

 

5,866,005

 

 

 

 

The aggregate intrinsic value of the options in the preceding table represents the total pre-tax intrinsic value for stock options, with an exercise price less than the Company’s TSX closing stock price as of the last trading day in the three months ended March 31, 2024 (approximately US$1.60), that would have been received by the option holders had they exercised their options on that date. There were 8,650,661 in-the-money stock options outstanding and 6,149,187 in-the-money stock options exercisable as of March 31, 2024.

 

No stock options were granted in the three months ended March 31, 2024. 

 

Restricted share units

 

On June 24, 2010, the Company’s shareholders approved the adoption of the Company’s restricted share unit plan (the “RSU Plan”), as subsequently amended and now known as the Restricted Share Unit and Equity Incentive Plan (the “RSU&EI Plan”). The RSU&EI Plan was approved by our shareholders most recently on June 2, 2022.

Eligible participants under the RSU&EI Plan include directors and employees of the Company. Granted RSUs are redeemed on the second anniversary of the grant. Upon an RSU redemption, the holder of the RSU will receive one common share, for no additional consideration, for each RSU held.

 

Activity with respect to RSUs is summarized as follows:

 

Restricted Share Unit Activity

 

Outstanding

RSUs

 

 

Weighted-average

Grant Date

Fair Value

 

 

 

#

 

 

$

 

December 31, 2023

 

 

641,910

 

 

 

1.33

 

 

 

 

 

 

 

 

 

 

Exercises

 

Nil

 

 

Nil

 

 

 

 

 

 

 

 

 

 

March 31, 2024

 

 

641,910

 

 

 

1.33

 

 

Stock-based compensation expense from RSUs was $0.1 million for the three months ended March 31, 2024, and $0.1 million for the three months ended March 31, 2023.

 

As of March 31, 2024, there was approximately $0.5 million of unamortized stock-based compensation expense related to the RSU&EI Plan. The expenses are expected to be recognized over the remaining weighted-average vesting periods of 1.4 years under the RSU&EI Plan.

 

As of March 31, 2024, outstanding RSUs were as follows:

 

Number

of RSUs

 

 

Weighted-average

Remaining

Contractual

Life

 

 

Aggregate

Intrinsic

Value

 

 

Redemption

Date

 

#

 

 

years

 

 

$

 

 

 

 

 

332,850

 

 

 

0.8

 

 

 

532,560

 

 

2025-01-04

 

 

309,060

 

 

 

1.7

 

 

 

494,496

 

 

2025-12-07

 

 

641,910

 

 

 

1.2

 

 

 

1,027,056

 

 

 

 

 

No restricted share units were granted in the three months ended March 31, 2024.

 

Warrants

 

In February 2021, the Company issued 16,930,530 warrants to purchase 8,465,265 of our common shares at $1.35 per full share. 

 

In February 2023, the Company issued 39,100,000 warrants to purchase 19,550,000 of our common shares at $1.50 per full share.

Activity with respect to warrants is summarized as follows:

 

 Warrant Activity

 

 Outstanding

Warrants

 

 

 Number of

Shares to be

Issued

Upon Exercise

 

 

 Per Share

Exercise Price

 

 

 

#

 

 

#

 

 

$

 

December 31, 2023

 

 

55,417,500

 

 

 

27,708,750

 

 

 

1.46

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 Exercised

 

 

(16,376,500 )

 

 

(8,188,250 )

 

 

1.35

 

 

 

 

 

 

 

 

 

 

 

 

 

 

March 31, 2024

 

 

39,041,000

 

 

 

19,520,500

 

 

 

1.50

 

 

We received $11.1 million from warrants exercised in the three months ended March 31, 2024.

 

As of March 31, 2024, outstanding warrants were as follows:

 

Exercise

Price

 

 

Number

of Warrants

 

 

Weighted-average

Remaining

Contractual

Life

 

 

Aggregate

Intrinsic

Value

 

 

Expiry

 

$

 

 

#

 

 

years

 

 

$

 

 

 

 

 

1.50

 

 

 

39,041,000

 

 

 

1.9

 

 

 

1,952,050

 

 

2026-02-21

 

 

1.50

 

 

 

39,041,000

 

 

 

1.9

 

 

 

1,952,050

 

 

 

 

 

Fair value calculation assumptions for stock options, restricted share units, and warrants

 

The fair value of stock options are determined using the Black-Scholes model on their respective grant dates.  The fair value of restricted share units are determined using the Intrinsic Value Method on their respective grant dates. 

 

The Company estimates expected future volatility based on daily historical trading data of the Company’s common shares. The risk-free interest rates are determined by reference to Canadian Benchmark Bond Yield rates with maturities that approximate the expected life. The Company has never paid dividends and currently has no plans to do so. Forfeitures and expected lives were estimated based on actual historical experience.

 

Share-based compensation expense related to stock options and restricted share units is recognized net of estimated pre-vesting forfeitures, which results in expensing the awards that are ultimately expected to vest over the expected life.